![Neil Kumar](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Neil Kumar
Chief Executive Officer at
EIDOS THERAPEUTICS, INC.
Net worth: 378 M $ as of 2026-06-29
Profile
Founder of BridgeBio Pharma, Inc. and BridgeBio Pharma LLC, Neil Kumar holds the position of Chief Executive Officer & Director at BridgeBio Pharma, Inc. and Chief Executive Officer & Director at BridgeBio Pharma LLC and Chief Executive Officer at Eidos Therapeutics, Inc. (both are subsidiaries of BridgeBio Pharma, Inc.). Neil Kumar is also on the board of PellePharm, Inc., Navire Pharma, Inc. and LianBio. Dr. Kumar previously was Associate Principal at McKinsey & Co., Inc., Principal at Third Rock Ventures LLC and Vice President-Business Development of MyoKardia, Inc. He received an undergraduate degree and a graduate degree from Stanford University and a doctorate from Massachusetts Institute of Technology.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2026-06-04 | 5,077,460 ( 2.59% ) | 378 M $ | 2026-06-29 | |
Maze Therapeutics, Inc.
 Maze Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops medicine for cardiovascular, renal and metabolic diseases -.--% | 2026-03-26 | 0 ( -.--% ) | - $ | 2026-06-29 |
LIANBIO -.--% | 2023-04-09 | 0 ( -.--% ) | - $ | 2026-06-29 |
Neil Kumar active positions
| Companies | Position | Start |
|---|---|---|
| LIANBIO | Director/Board Member | 2019-09-30 |
| EIDOS THERAPEUTICS, INC. | Chief Executive Officer | 2016-02-29 |
| BRIDGEBIO PHARMA, INC. | Founder | 2014-12-31 |
BridgeBio Pharma LLC
 BridgeBio Pharma LLC BiotechnologyHealth Technology Discovers and develops medicines for patients with genetic diseases | Founder | 2014-12-31 |
BridgeBio Chemistry, Inc. | President | - |
Origin Biosciences, Inc.
 Origin Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Develops biopharmaceuticals | President | - |
Phoenix Tissue Repair, Inc.
 Phoenix Tissue Repair, Inc. Pharmaceuticals: MajorHealth Technology Develops biopharmaceuticals | President | - |
Calcilytix Therapeutics, Inc. | President | - |
Adrenas Therapeutics, Inc. | Treasurer | - |
| ░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░ | - |
| ░░░░░░░░░ ░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | - |
Former positions of Neil Kumar
| Companies | Position | End |
|---|---|---|
| ░░░░░ ░░░░ ░░░░░░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░░ ░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░ ░░░░░░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Training of Neil Kumar
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
80
1st degree connections
19
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 19 |
|---|---|
MyoKardia, Inc.
 MyoKardia, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that discovers, develops and commercializes therapies for the treatment of cardiovascular diseases | Health Technology |
PellePharm, Inc.
 PellePharm, Inc. BiotechnologyHealth Technology Develops biotechnologies to cure dermatological diseases | Health Technology |
McKinsey & Co., Inc.
 McKinsey & Co., Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a management consulting firm | Commercial Services |
Stanford University
 Stanford University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Massachusetts Institute of Technology
 Massachusetts Institute of Technology Finance/Rental/LeasingFinance Functions as a College/University | Finance |
Third Rock Ventures LLC
 Third Rock Ventures LLC Investment ManagersFinance Third Rock Ventures invests in companies located in the United States. The firm focuses on the healthcare. It participates in early stage capital requirements. The firm also acts as lead investor. | Finance |
BridgeBio Pharma LLC
BridgeBio Pharma LLC BiotechnologyHealth Technology Discovers and develops medicines for patients with genetic diseases | Health Technology |
Eidos Therapeutics, Inc.
 Eidos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage biopharmaceutical company | Health Technology |
QED Therapeutics, Inc.
 QED Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops biopharmaceuticals | Health Technology |
Origin Biosciences, Inc.
Origin Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Develops biopharmaceuticals | Health Technology |
Phoenix Tissue Repair, Inc.
Phoenix Tissue Repair, Inc. Pharmaceuticals: MajorHealth Technology Develops biopharmaceuticals | Health Technology |
Navire Pharma, Inc.
 Navire Pharma, Inc. Pharmaceuticals: MajorHealth Technology Develops biopharmaceuticals | Health Technology |
Maze Therapeutics, Inc.
Maze Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops medicine for cardiovascular, renal and metabolic diseases | Health Technology |
BridgeBio Pharma, Inc.
 BridgeBio Pharma, Inc. BiotechnologyHealth Technology Develops medicines for genetic diseases to patients | Health Technology |
Adrenas Therapeutics, Inc. | |
BridgeBio Services, Inc. | |
Calcilytix Therapeutics, Inc. | |
LianBio
 LianBio BiotechnologyHealth Technology Operates as a biotechnology company focused on bringing paradigm-shifting medicines to patients | Health Technology |
BridgeBio Chemistry, Inc. |
- Stock Market
- Insiders
- Neil Kumar
Choose MarketScreener 
